Medical tests

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.

Worldwide Companion Diagnostics Market to 2026 to be Driven by Significant Partnerships and Collaborations for Development

Retrieved on: 
Monday, September 6, 2021
Companies, Life sciences, Industry economics), Medical tests, Medical software, Qiagen, Molecular diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies

The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.

Key Points: 
  • The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.
  • In addition, improvements in regulatory guidelines and the growing need for targeted therapies are also driving the global companion diagnostics market.
  • Increasing incidences of cancer has driven the adoption of companion diagnostics for developing drugs in cancer treatment.
  • Oncology is the leading segment in terms of revenue in global companion diagnostics market with around 82.72% market share.

AMI Partners with LifeSign To Provide the Status COVID-19/Flu A&B Test for Upcoming Respiratory Season

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Coronaviridae, Clinical medicine, Medical tests, Medical terminology, Nasopharyngeal swab, Respiratory therapy, Rapid diagnostic test, COVID-19, Severe acute respiratory syndrome, DiaSorin, Curative

Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.

Key Points: 
  • Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.
  • said Samatha Young, Head of Global Sales at AMI .
  • The LifeSign Status COVID-19 Flu A&B rapid test is a qualitative assay for the simultaneous detection of influenza A&B antigen and SARS CoV-2 antigen from nasopharyngeal swabs obtained from patients/Flu rapid combo test on the market.
  • As a leader in rapid diagnostics, LifeSign is excited and proud to partner with AMI.

PCR Molecular Diagnostics Market Research Report 2021 - Global Growth, Trends, COVID-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Health, Other Health, Biotechnology, Branches of biology, Natural sciences, Biology, Laboratory techniques, Molecular biology, Medical tests, Amplifiers, Molecular diagnostics, Polymerase chain reaction

The "PCR Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PCR Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The PCR Molecular Diagnostics market is expected to grow with an estimated CAGR of 3.5%, over the forecast period.
  • Though COVID 19 has a major impact on the medical industry, the PCR Molecular Diagnostics market is on a positive trend.
  • The rising prevalence of cancer and infectious diseases is also a major factor that drives PCR molecular diagnostics market.

Facedrive Becomes a Distributor of COVID-19 Rapid Antigen Tests for Workplace Screening in Small and Medium Sized Organizations

Retrieved on: 
Tuesday, August 3, 2021
Medical Supplies, Automotive, Online Retail, Technology, Professional services, Health, Small business, Infectious diseases, Retail, Alternative Vehicles, Fuels, Internet, Medical tests, Medical terminology, Articles, Rapid diagnostic test, E-government

Ultimately, the Company is aspiring to make the Government of Canadas rapid testing program accessible to all eligible businesses nationwide.

Key Points: 
  • Ultimately, the Company is aspiring to make the Government of Canadas rapid testing program accessible to all eligible businesses nationwide.
  • In the first month of Facedrives collaborative efforts with the Government of Canada, Facedrive will distribute rapid tests through its extensive partner network.
  • In all, registration, order, pick-up, delivery, training and reporting has been made quick and easy through the Facedrive Online Portal https://rapidtest.facedrive.com/ .
  • As our economy begins to safely reopen, rapid resting and workplace screening will support small businesses and help them recover quicker.

The Worldwide Contract Research Organization Services Industry is Expected to Reach $86.5 Billion by 2026

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Quality, Laboratory techniques, Medicine, Cell biology, Clinical pathology, Medical tests, Validation, Cleaning validation, Flow cytometry, Cytometry

6.3.6.1 Increasing Use of Molecular Imaging, Flow Cytometry, and Immunohistochemistry to Boost Segment

Key Points: 
  • 6.3.6.1 Increasing Use of Molecular Imaging, Flow Cytometry, and Immunohistochemistry to Boost Segment
    6.4.6.1 Used to Ensure Long-Term Quality, Safety, and Efficacy of Pharmaceutical Products
    6.4.7.1 Demand for Analytical Method Validation, Cleaning Validation, and Microbial Testing to Propel Segment Growth

Vaccinate or Get Tested: Federal & State Governments, CDC, Corporations Issue New Directives as Delta Variant Fuels Demand for Recuro COVID At-Home or Onsite Testing Platform

Retrieved on: 
Monday, August 2, 2021
Technology, Insurance, Infectious diseases, Hospitals, Professional services, Practice Management, Managed care, Health, Data management, COVID-19 testing, Medical specialties, Medicine, Clinical medicine, Immunology, Passports, COVID-19, Medical tests

With advances in COVID-19 testing, rapid antigen and PCR testing with immediate results are available under the Recuro Health testing solution, says Michael Gorton, CEO and founder, Recuro Health.

Key Points: 
  • With advances in COVID-19 testing, rapid antigen and PCR testing with immediate results are available under the Recuro Health testing solution, says Michael Gorton, CEO and founder, Recuro Health.
  • What distinguishes our approach from the myriad of programs on the market is a structured process for test distribution and administration, validation of results and back-end reporting.
  • An avalanche of requests from employers nationwide for Recuros at-home or on-site COVID testing platform follows these announcements:
    Presidential directive requiring all federal employees to be vaccinated against COVID-19 or submit to regular testing.
  • Cases are rising in all 50 states but several states have low vaccination rates which are accounting for the Delta variant surge.

eMed™ Bolsters Airline Partnerships with Convenient COVID-19 Testing for International Travelers

Retrieved on: 
Thursday, July 29, 2021
Articles, Medicine, Medical tests, Medical terminology, Technology, Assistive technology, Telehealth, Walgreens, Rapid diagnostic test

Travelers can now visit their respective airlines website, eMed.com, or select Walgreens pharmacy locations to purchase a rapid antigen home test kit for COVID-19 that is administered through the eMed site.

Key Points: 
  • Travelers can now visit their respective airlines website, eMed.com, or select Walgreens pharmacy locations to purchase a rapid antigen home test kit for COVID-19 that is administered through the eMed site.
  • International travelers are looking for ways to stay safer and simplify their travel experience, said Dr. Patrice Harris, eMed Co-Founder and CEO.
  • This is a best-in-class approach for rapid testing of travelers returning to the skies.
  • eMed ( www.eMed.com ) is a telehealth company democratizing healthcare with a digital point-of-care platform that provides fast, easy and affordable at-home health care testing, supervised and guided online by eMed Certified Guides.

Qorvo Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Platform Validated in National Institutes of Health (NIH) Funded Study

Retrieved on: 
Wednesday, July 28, 2021
Medicine, Medical tests, Branches of biology, Medical terminology, Academic disciplines, Immunologic tests, Biotechnology, Molecular biology, Point-of-care testing, Rapid antigen test, Sensitivity and specificity

Atlantas Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test.

Key Points: 
  • Atlantas Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test.
  • Three pediatric samples that tested negative on the Qorvo Omnia Antigen Test had Cycle threshold (Ct) values greater than 38 on the Hologic system, indicating very low viral loads in those samples.
  • Overall, the investigators found the Qorvo Omnia platform design intuitive and easy to use while producing rapid test results compared to high-sensitivity molecular testing systems, with test results within 20 minutes from sample collection.
  • This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health.

iXensor Levels Up PixoTest Covid-19 Ag Test With The Launch Of PixoHealth Data Management Platform As The Security Solution For The New Normalcy

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Branches of biology, Medical terminology, Medical tests, Health sciences, Point-of-care testing, COVID-19, Glucose meter, Web portal, Severe acute respiratory syndrome coronavirus

In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.

Key Points: 
  • In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.
  • The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup.
  • In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
  • In 2017, iXensor introduced the PixoTest Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test.